<DOC>
	<DOC>NCT02726477</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of Wuling San, a traditional Chinese medicine, in reducing arm volume excess in women with stage I-II breast cancer related unilateral lymphedema.</brief_summary>
	<brief_title>Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema</brief_title>
	<detailed_description>The investigators will aim to enroll 200 female adult patients (aged between 20 and 40 years) of all ethnicities/races, who have been referred to the Fourth Affiliated Hospital of Guangxi Medical University for breast cancer related unilateral lymphedema. The investigators will be using a standardized data collection form in this study, where standard of care will be practiced and the patients are not placed at additional risk from participating in this study. However, as the investigators are collecting data prospectively, all participants will sign consent.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lymphedema</mesh_term>
	<criteria>Women completed all primary and adjuvant treatments (surgery, chemotherapy, radiotherapy) age 2040 with unilateral BCRL, stage I or II, BMI of 1825 Volume difference â‰¥300 mL between the normal and lymphedematous upper extremity based on perometry evaluation No evidence of breast cancer recurrence At least 6 months postoperative from axillary lymph node dissection Bilateral lymphedema or stage III lymphedema History of bilateral axillary lymph node dissection Recent history of cellulitis in the affected extremity (within last 3 months) Recurrent breast cancer or other malignancy Current (within last month) use of chemotherapy for breast or other malignancy Current (within last 3 months) use of radiation for breast or other malignancy Recent (within last month) or current intensive MLD and/or short stretch bandage use Unstable lymphedema (i.e. worsening symptoms/measurements in the past 3 months) Pregnant or nursing (lactating) women Patients that take drugs like diosmin at the time of enrollment, or within 30 days. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer. Unable to comply with the protocol, measurement and followup schedule.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>